Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Donafenib”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07157306
What this trial is testing

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT06239298
What this trial is testing

ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Who this might be right for
Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 130
Large-scale testing (Phase 3)Ended earlyNCT05171166
What this trial is testing

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Who this might be right for
Hepatocellular Carcinoma
Peking University 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07353827
What this trial is testing

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT05545124
What this trial is testing

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Who this might be right for
Hepatocellular Carcinoma
Henan Cancer Hospital 32
Not applicableUnknownNCT05200221
What this trial is testing

A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice

Who this might be right for
DonafenibHepatocellular Carcinoma
Shanghai Zhongshan Hospital 300
Testing effectiveness (Phase 2)UnknownNCT04612712
What this trial is testing

Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Who this might be right for
Advanced Gastrointestinal Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 42
Testing effectiveness (Phase 2)Looking for participantsNCT06787911
What this trial is testing

Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer

Who this might be right for
Thyroid Cancer
Yu Wang 14
Testing effectiveness (Phase 2)UnknownNCT04503902
What this trial is testing

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 46
Testing effectiveness (Phase 2)Study completedNCT02870569
What this trial is testing

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 48
Testing effectiveness (Phase 2)Study completedNCT05162352
What this trial is testing

Donafenib Plus Sintilimab for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 30
Testing effectiveness (Phase 2)UnknownNCT05138159
What this trial is testing

Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Who this might be right for
Metastatic Pancreatic Cancer
Fudan University 10
Not applicableUnknownNCT06233994
What this trial is testing

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Changsha Taihe Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05166772
What this trial is testing

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07230314
What this trial is testing

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

Who this might be right for
Unresectable Hepatocellular Carcinoma
Jinling Hospital, China 34
Not applicableLooking for participantsNCT06609876
What this trial is testing

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Who this might be right for
Hepatocellular CarcinomaMicrowave AblationDonafenib+1 more
Sun Yat-sen University 108
Early research (Phase 1)Active Not RecruitingNCT04605185
What this trial is testing

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Who this might be right for
Unresectable Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 18
Large-scale testing (Phase 3)Study completedNCT02870582
What this trial is testing

Donafenib for Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 536
Testing effectiveness (Phase 2)Looking for participantsNCT06685289
What this trial is testing

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Who this might be right for
Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University 70
Testing effectiveness (Phase 2)Looking for participantsNCT06498622
What this trial is testing

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Who this might be right for
Hepatocellular Carcinoma
Anhui Provincial Hospital 45
Load More Results